

RESEARCH ARTICLE

Open Access

# Gene silencing of $\beta$ -galactosamide $\alpha$ -2,6-sialyltransferase 1 inhibits human influenza virus infection of airway epithelial cells

Dong Wu<sup>1,2</sup>, Wenbo Huang<sup>1</sup>, Yutao Wang<sup>1</sup>, Wenda Guan<sup>1</sup>, Runfeng Li<sup>1</sup>, Zifeng Yang<sup>1\*</sup> and Nanshan Zhong<sup>1\*</sup>

## Abstract

**Background:** Human influenza virus hemagglutinin prefers to use sialic acid (SA) receptors via  $\alpha$ -2,6 linkages. The  $\beta$ -galactoside  $\alpha$ -2,6-sialyltransferase I (ST6Gal I) protein is encoded by the ST6GAL1 gene and is responsible for the addition of  $\alpha$ -2,6 linked SA to the Gal $\beta$ 1-4GlcNAc disaccharide of glycans and glycoproteins found on the cellular surface. Therefore, ST6GAL1 could be a potential target for anti-influenza therapeutics. We used specific small interfering RNAs (siRNAs) to block expression of ST6GAL1 and limit distribution of SA receptors on the surface of airway epithelial cells.

**Results:** The siRNA duplexes we used inhibited ST6GAL1 mRNA expression and subsequent expression of the encoding protein. As a result, synthesis of  $\alpha$ -2,6 SA galactose was inhibited. Adsorption of influenza virus particles to the surface of cells transfected with appropriate specific siRNAs was significantly reduced. Intracellular viral genome copy number and virus titer within the supernatant of cells transfected with siRNAs was significantly reduced in a dose-dependent manner compared with those for untransfected cells and cells transfected with non-specific siRNAs.

**Conclusions:** We used siRNAs targeting ST6GAL1 to inhibit the expression of certain cell surface receptors, thereby preventing virus adsorption. This resulted in the inhibition of human influenza virus infection. Our findings are a significant development in the identification of potential new anti-influenza drug targets.

**Keywords:** Influenza virus, Receptors, Sialyltransferase, RNAi

## Background

Influenza virus infections are considered a significant public health problem given that they cause seasonal epidemics and recurring pandemics [1]. There were more than 29,000 cases of infections, and 3,000 human deaths attributed to the 2009 global H1N1 influenza pandemic [2]. Because of the high mutation rates of the viral genome, vaccines and drugs initially directed against the virus often become ineffective [3,4]. Therefore, measures are urgently needed to prevent and treat influenza virus infections, especially for high-risk groups and in the event of another pandemic. Certain host cell factors involved in the viral infection cycle have attracted interest

as therapeutic targets because these are crucial for viral infections. Targeting these factors might inhibit infection, and there is the added advantage that they are less prone to mutations [5-7].

Sialic acid (SA) molecules, found at the non-reducing terminal position of glycoproteins or glycolipids on the surface of cells, are binding targets for influenza A virus (IAV) hemagglutinin (HAs) [8]. The HAs of human IAVs preferentially bind to  $\alpha$ -2,6 linked SA, which is abundantly expressed in the human respiratory tract. The HA proteins of avian IAVs prefer  $\alpha$ -2,3 linked SA as a receptor, as it is predominant in the avian enteric tract [9]. The binding of HA to its appropriate receptor is crucial for the initiation of infection and therefore serves as a potential therapeutic target. The novel sialidase fusion protein, DAS181 (Fludase), enzymatically removes SAs from the respiratory epithelium and exhibits potent antiviral activity against influenza A and B viruses [10]. Sialyltransferases

\* Correspondence: jeffyah@163.com; nanshan@vip.163.com

<sup>1</sup>State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, 1st KangDa Road, Guangzhou, China  
Full list of author information is available at the end of the article

are key enzymes that regulate the biosynthesis of sialylated oligosaccharide sequences [11]. Weinstein *et al.* concluded that one enzyme,  $\beta$ galactoside  $\alpha$ 2,6sialyltransferase I (ST6Gal I), encoded by ST6GAL1, was responsible for the addition of  $\alpha$ -2,6 SAs to the Gal $\beta$ 1-4GlcNAc disaccharide found on the glycans of N-linked and some O-linked glycoproteins [12]. Lin *et al.* found that antisense-oligodeoxynucleotides targeting ST6GAL1 mRNAs could inhibit the enzymatic activity of ST6Gal I, and reduced 2,6-sialylation at the cell surface [13,14].

Numerous studies involving small interfering RNAs (siRNAs) in the treatment of viral infections have been conducted [15-17], including our successful application of siRNAs to treat severe acute respiratory syndrome (SARS)-infected rhesus macaques [18]. Qe *et al.* used siRNAs specific for conserved regions of the influenza virus genome; these proved to be potent inhibitors of influenza virus replication *in vitro* and *in vivo* [19,20]. However, siRNAs solely targeting the genes of influenza viruses are unlikely to be sufficient in eliminating infection because there is a high possibility of generating resistant mutants. Therefore siRNAs targeting host cellular determinants crucial for viral entry and/or replication could be a more efficacious antiviral therapy.

Our study was designed to evaluate siRNAs targeting ST6GAL1 in airway epithelial cells. We designed four siRNA duplexes and screened their ability to down-regulate ST6GAL1 expression and affect the biosynthesis of  $\alpha$ -2,6-linked SA in human respiratory tract epithelium. The antiviral effects of selected siRNA duplexes were demonstrated using viral binding assays, and by determining cytoplasmic viral genome copy numbers and virus titers in culture supernatants.

## Results

### ST6Gal I expression in siRNA-transfected A549, HBE, and HEp-2 respiratory epithelial cells

Using qPCR assays, we determined there was an 80–90% reduction in ST6GAL1 mRNA expression levels up to 48 h post-transfection (Figure 1A,B). Both ST6GAL1-siRNA01 and -02 were more potent than the other siRNA candidates. Their effects were verified using western blot assays. In cells transfected with the selected ST6GAL1 siRNAs, ST6Gal I expression was substantially lower than in those transfected with control siRNAs and untransfected cells (Figure 1D). This roughly corresponds to the reduction in mRNA levels as observed by qPCR.

### Transduced epithelial cells showed normal levels of viability

The concentration of ST6GAL1 siRNAs we used (2.5–25 nM) did not adversely affect the number of viable cells, nor affect cell morphology (data not shown) of A549, HBE, and HEp-2 cells (Figure 1E and Additional

file 1: Figure S1). When we used siRNAs at 50 nM some cytotoxicity was observed. Based on these results, we used siRNAs at 10 nM in the remainder of our experiments.

### Down-regulation of influenza virus receptors SA $\alpha$ 2,6Gal

Expression of SA $\alpha$ 2,6Gal receptors was observed on the surface of cultured human A549 cells (Figure 2A). Treatment with ST6GAL1 siRNAs significantly reduced the number of SA $\alpha$ 2,6Gal receptors at the cell surface (Figure 2C) compared with control siRNAs (Figure 2B) and untransfected cells (Figure 2A). Similar results were seen for HBE and HEp-2 cells (Additional file 1: Figure S2). Our FACS analysis of A549 cells revealed that ST6GAL1 siRNA-transduced cells had an 89% decrease in SA $\alpha$ 2,6Gal expression. Cells treated with control siRNAs and untreated cells displayed normal levels of SA $\alpha$ 2,6Gal expression (Figure 1C).

### Receptor specificity of viruses

All virus strains tested bound to CRBCs, which expressed both  $\alpha$ 2,3- and  $\alpha$ 2,6-linked SA. The H9N2 virus preferentially bound to SA $\alpha$ 2,3Gal-resialylated CRBCs, whereas the human H1N1 and seasonal human H3N2 influenza virus preferentially bound to the SA $\alpha$ 2,6Gal-resialylated CRBCs (Figure 3).

### siRNA-transduced respiratory cells were resistant to viral challenge


A reduction in viral yield was seen in ST6GAL1 siRNA-transduced A549 cells challenged with the H3N2 and pdmH1N1 strains as compared with control cells (Figure 4A,B). Similar results were observed for HBE and HEp-2 cells (Additional file 1: Figure S3). No differences were observed when cells were infected with the avian H9N2 virus (Figure 4C).

### Inhibition of ST6GAL1 expression affects virus binding and internalization

Virus particles were abundant on the surface of A549 cells transfected with control siRNAs, and those infected with viruses (Figure 5A,B). However, there was a reduction in the number of bound virus particles for cells treated with ST6GAL1 siRNAs (Figure 5C). The genome copy number of viruses was reduced following transfection of the various cell lines (A549, HBE, and HEp-2) with ST6GAL1 siRNAs (Figure 4D) prior to viral infection.

### The tested siRNAs did not induce an interferon response

The expression of IFN- $\beta$  in supernatants of siRNA-transfected cell lines (A549, HBE and HEp-2) was not detected. As a positive control, a long double-stranded RNA that is known to induce the expression of IFN- $\beta$  was included (Figure 4E).




## Discussion

In our study, we were able to demonstrate that down-regulation of the major influenza receptor, SA $\alpha$ 2,6Gal, in respiratory epithelial cells was a promising approach to prevent viral entry and establishment of an infection. Most human influenza infections are caused by virus strains transmitted *via* an airborne route from the human respiratory tract, although there are some reports of avian influenza viruses directly infecting humans [21,22]. We designed siRNAs targeting ST6GAL1, in an attempt to inhibit pdmH1N1 and H3N2 virus infection in Hep-2, HBE, and A549 cells, which are representative of the upper, middle and lower respiratory tract epithelial cells, respectively, without inducing an interferon response.

Treatment with siRNAs is not dependent upon a functional immune system. Therefore siRNA therapies could be as effective in elderly or immunocompromised individuals as in immunocompetent individuals [23]. The siRNAs targeting ST6GAL1 that we used in this current

study could be ideal in preventing influenza infection in patient groups with low immunity. Our results pertaining to virus binding indicate that ST6GAL1-specific siRNAs reduce the number of IAV virions that attach to epithelial cells, because of reduced expression of SA $\alpha$ 2,6Gal on the cell surface.


Recent studies have suggested that some siRNAs could have side effects [24] that adversely affect cell viability. We demonstrated that the effective dose (10 nM) of siRNAs, under the conditions tested, was not toxic to respiratory epithelial cells *in vitro*. However, we did notice that expression levels of receptors were substantially diminished as a result of siRNA targeting. Influenza viruses naturally infect epithelial cells in the upper respiratory tract and the lungs of humans. Thus, siRNAs can be administered by inhalation. This would result in much higher local siRNA concentrations than could be achieved by parenteral injection, without adversely affecting epithelial cells [23]. Studies focusing on these aspects are currently underway in our laboratories.




**Figure 2 Treatment with ST6GAL1 siRNAs inhibited SA $\alpha$ 2,6Gal expression on cell surfaces.** A549 cells were treated with ST6GAL1 or control siRNAs. SA $\alpha$ 2,6Gal was stained with SNA-FITC (green) and cell nuclei were counterstained with DAPI (blue). **(A)** Untreated cells. **(B)** Control siRNAs. **(C)** ST6GAL1 siRNAs.

In other studies, investigators found that human influenza viruses can still infect ST6GAL1 knock-out mice, achieving similar titers in the lung and trachea as compared with wild-type animals [25]. A possible explanation for this is that there was greater efficiency of infection as a result of a deficient systemic influenza-specific humoral response in these ST6GAL1 knock-out mice [26]. There are two major types of SA $\alpha$ 2,3Gal, which differ in their penultimate bond (Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-3GalNAc or Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc) and these are synthesized by different enzymes [27-29]. Some human influenza virus strains propagated in allantoic cavities are able to bind to both SA $\alpha$ 2,6Gal and SA $\alpha$ 2,3Gal [9,25,30]. When recombinant rat  $\alpha$ 2,3-sialyltransferase was used to reconstitute sialic acids, only one type of

galactose was linked to other glycans through  $\beta$ -1,3 but not  $\beta$ -1,4 linkages [31-33]; however, it is possible that other strains maintain the ability to bind to Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc. Thus, SA $\alpha$ 2,3Gal (Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc) present in these mice can compensate for the loss of SA $\alpha$ 2,6Gal [34]. Monteerarat *et al.* [35] reported that suppression of SA $\alpha$ 2,3Gal expression by siRNAs against another sialyltransferase,  $\beta$ -galactoside  $\alpha$ -2,3-sialyltransferase 4 (ST3GAL4) could inhibit H5N1 avian influenza virus infection. The findings from our current study support the conclusions of Monteerarat *et al.*, and we have further extended these to airway epithelial targets of human IAV infection. A combination of these two types of siRNAs might result in broader spectrum synergistic activities, depending upon their targets.



**Figure 3 Receptor specificity of virus strains.** **(A)** Unmodified (left) and VCNA-treated CRBCs (right). **(B)** SA $\alpha$ 2,6Gal-resialylated CRBCs hemagglutinate the H3N2 and pdmH1N1 viruses (left). SA $\alpha$ 2,3Gal-resialylated CRBCs hemagglutinate the H9N2 virus (right). Top: two hemagglutination units. Bottom: 1:2 dilution.




## Conclusions

We demonstrated the *in vitro* efficacy of siRNAs targeting ST6GAL1 in respiratory epithelial cells for the prevention of IAV infections at the virus entry stage. Further *in vivo* preclinical testing is required to determine the suitability of these siRNAs for use in humans.

## Methods

### Cells and viruses

We used Madin–Darby canine kidney (MDCK) cells for virus propagation and 50% tissue culture-infective dose (TCID<sub>50</sub>) titration assays. MDCK cells were in minimal essential medium (MEM; Gibco, Carlsbad, CA, USA)



supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco) at 37°C/5% CO<sub>2</sub>. The A549 human lung carcinoma, human bronchial epithelium (HBE), and human laryngeal epidermoid carcinoma (HEp-2) cells were used for transfection experiments. These cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C 5% CO<sub>2</sub>. We used a 2009 pandemic influenza A (H1N1) virus (pdmH1N1), strain A/Guangzhou/GIRD07/2009 (GenBank Accession No. HM\_014326-HM\_014333). A seasonal H3N2 influenza A virus (A/Guangdong/520/2009) was isolated from a patient with influenza-like symptoms. An influenza A H9N2 isolate (A/Chicken/Guangdong/SS/94) was kindly provided by South China Agricultural University. The pdmH1N1 and H3N2 viruses were grown in MDCK cells at 35°C, while the H9N2 virus was propagated in allantoic cavities of 10-day-old embryonated hens' eggs at 37°C. All experiments with pdmH1N1 and H9N2 viruses were conducted under biosecurity level three conditions, and higher.

#### Preparation and transfection of siRNAs

The siRNAs against ST6GAL1 were designed using BLOCK-iT™ RNAi Designer [36] and synthesized by Invitrogen (Invitrogen, Carlsbad, CA, USA). Sequences are available in Additional file 1: Table S1. As a negative control, we used non-targeting Allstars® siRNAs (Qiagen, Valencia, CA, USA). All siRNA duplexes were double-stranded RNA molecules comprising 21 nt with a dTdT overhang at the 3' ends [37]. Target sequences were subjected to a Basic Local Alignment Search Tool (BLAST) search against GenBank to ensure they were unique to ST6GAL1. Airway epithelial cell lines (A549, HBE, and HEp-2) were transfected with either ST6GAL1 or non-targeting Allstars® siRNAs using Lipofectamine® RNAiMax (Invitrogen) according to the manufacturer's instructions. At different time points post-transfection, cells were either infected with influenza virus or harvested for downstream experiments.

#### Detection of ST6GAL1 and ST6Gal I

Expression of ST6GAL1 was detected using real-time reverse transcription polymerase chain reaction (qPCR) assays. Expression of the ST6Gal I protein was determined by western blotting. Respiratory epithelial cells (A549, HBE, and HEp-2) were transfected with control or ST6GAL1 siRNAs (2.5–50 nmol). At 48 h post-transfection we used an RNeasy Mini kit (Qiagen) for RNA extraction according to the manufacturer's instructions. The extracted total RNA (500 ng/sample) was then used for cDNA synthesis. The resulting cDNA was amplified in a 20-µL reaction containing ST6GAL1-specific forward (0.25 µmol) and reverse

(0.25 µmol) primers (Additional file 1: Table S2), and 1× Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Reactions were subjected to thermal cycling with an IQ5 System (Bio-Rad, Hercules, CA, USA) involving an initial 10-min denaturation step at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Fluorescence signals from these reactions were captured at the end of the 60°C extension step for each cycle. To determine the specificity of the assay, amplicons were subject to melting curve analysis after the 40th cycle (65–95°C, 0.1°C/s). Our data were analyzed using the 2<sup>-ΔΔCT</sup> method, according to the manufacturer's instructions, with ST6GAL1 expression levels normalized to β-actin mRNA levels.

After transfection for 48 h, A549 cells were lysed in 50 mM Tris-HCl buffer (pH 7.4) containing 1% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 20 µg/mL leupeptin, 4 mM sodium fluoride, and 200 µM sodium pervanadate. Protein concentrations in the lysates were determined with a BCA assay kit (Pierce, Rockford, IL, USA). Proteins in lysates were resolved under reducing conditions for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). We probed polyvinylidene fluoride (PVDF) membranes with 5 µg/mL of a rabbit antihuman ST6Gal I polyclonal antibody (Abcam, Cambridge, MA, USA) followed by a horseradish peroxidase (HRP) conjugated antirabbit IgG secondary antibody (Abcam). Specific signals were visualized using an ECL kit (Pierce). Protein concentrations between wells were normalized using HRP-conjugated β-actin-specific monoclonal antibodies (Sigma-Aldrich, St. Louis, MO, USA).

#### Cell viability

Cultured cells in the logarithmic growth phase were trypsinized, seeded into 96-well plates, and transfected with ST6GAL1 (2.5–50 nmol) or control (10 nmol) siRNAs. At 24, 48, and 72 h post-transfection, cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays (Sigma-Aldrich). The absorbance at 492 nm was measured in a spectrophotometer (Molecular Devices, Palo Alto, CA, USA). Background values were subtracted from the average absorbance value obtained for each siRNA treatment and then compared with the value obtained when siRNAs were absent (100% viability). Each assay was performed in duplicate in at least four wells.

#### Detection of α-2,6 linked SA on the cell surface

The A549, HBE, and HEp-2 cells were treated with ST6GAL1 or control siRNAs and cultured for 72 h. Cells were washed with phosphate-buffered saline (PBS) and fixed in 3.7% formaldehyde in PBS for 30 min. For detection of sialic acid residues on the surface of cells, apical monolayers were blocked with 3% bovine serum

albumin (BSA; Merck, Darmstadt, Germany) in PBS for 30 min and then incubated with 5 µg/mL fluorescein isothiocyanate (FITC)-conjugated *Sambucus nigra* lectin (SNA; Vector Laboratories, Burlingame, CA, USA) for 1 h. To confirm the specificity of lectin binding, monolayers were treated with 50 mU *Vibrio cholerae* neuraminidase (VCNA; Roche, Almere, Netherlands) for 1 h prior to fixation and then examined with a rapid-scanning confocal laser microscope (Nikon Corp, Tokyo, Japan).

#### Flow cytometry

Approximately  $10^6$  cells transfected with control or ST6GAL1 siRNAs were scraped from the culture surface and washed twice with PBS containing 10 mM glycine, and then washed once with buffer 1 (50 mM Tris-HCl, 0.15 M NaCl, 1 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, pH 7.5). Cells were blocked with 3% BSA-PBS for 1 h on ice and washed in the same manner as described above. After centrifugation, the cell pellet was incubated with FITC-conjugated SNA at room temperature for 30 min, then washed and fixed with 1% paraformaldehyde. After another three washes with PBS, mean fluorescence intensities were determined on a fluorescence-activated cell sorter (FACS) Calibur flow cytometer (BD, San Jose, CA, USA) by counting a minimum of 10,000 events.

#### Receptor specificity of virus strains

To study the receptor-binding properties of the virus strains used, we enzymatically modified chicken red blood cells (CRBCs) to express either sialic acid (SA)-α2,6-Galactose (Gal) or SAα2,3Gal as previously described [38,39] with minor modifications. Briefly, SA was removed from 100 µL of 10% CRBCs using 50 mU VCNA at 37°C for 1 h. Subsequent resialylation was performed using 50 µL of 0.5 mU α2,3-(N)-sialyltransferase (Calbiochem, La Jolla, CA, USA) or 125 µL of 2 mU α2,6-(N)-sialyltransferase (Japan Tobacco, Shizuoka, Japan), and 1.5 mM cytidine monophospho-N-acetylneuraminic (CMP) sialic acid (Sigma-Aldrich) at 37°C for 30 or 60 min, respectively. Receptor specificity of the virus strains was then determined using standard hemagglutination assays with the modified CRBCs.

#### Influenza virus challenge of ST6GAL1-siRNA transduced epithelial cells

All challenge experiments were carried out at a multiplicity of infection (MOI) of 0.01 for 1 h in the presence of N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK)-trypsin (Sigma-Aldrich). Viral supernatants were harvested at various time points post-infection for TCID<sub>50</sub> assays. To obtain dose-response curves, a dilution series of siRNAs were added to cells in 96-well plates in triplicate. Cells were challenged and supernatants were examined as described above [40].

The titer of viruses in supernatants were determined using TCID<sub>50</sub> assays as previously described [20]. Briefly, MDCK cells were seeded onto flat-bottom 96-well plates ( $3 \times 10^4$  cells/well); 24 h later, serum-containing medium was removed and 25 µL of virus-containing supernatants (serially diluted ten-fold from  $10^0$  to  $10^{-8}$ ) was added to wells in triplicate. After incubation for 1 h, 175 µL of infection medium containing TPCK-trypsin (1.25 µg/mL) was added to each well. After incubation for 48 h at 37°C, the presence or absence of virus in culture supernatants was determined by hemagglutination of CRBCs. Virus titers were determined by interpolation of the dilution endpoint that infected 50% of wells. Virus titers are presented as log<sub>10</sub> TCID<sub>50</sub>.

#### Electron microscopy

Cells were transfected with control or ST6GAL1 siRNAs, then infected with virus at an MOI of 50, and chilled at 4°C for 90 min. Infected cells were harvested and washed three times with PBS, then fixed with 3% glutaraldehyde for 45 min at room temperature, and post-fixed with 1% osmium tetroxide. Fixed cells were dehydrated with increasing concentrations of acetone from 30% to 100% and embedded in an epoxy resin. Polymerization was conducted at 60°C for 48 h. Ultrathin sections were stained with uranyl acetate and lead citrate, and sections viewed and photographed with a Hitachi H-800 transmission electron microscope (Hitachi Co., Tokyo, Japan).

#### Quantitation of viral genome copies by qPCR

We extracted RNA 2 h after virus infection using a QIAamp RNA isolation kit (Qiagen). First-strand cDNA was synthesized using RNase H<sup>+</sup> reverse transcriptase (Invitrogen) and random primers. We then used 2 µL of cDNA for each qPCR assay, along with primers (Additional file 1: Table S2), fluorescent probe, and Master Mix (Applied Biosystems). Samples were subjected to thermal cycling on an IQ5 System (Bio-Rad, Hercules, CA, USA): 42°C for 5 min; 95°C for 10 s; and 40 cycles of 95°C for 5 s and 60°C for 30 s. Expression levels of viral RNAs were normalized to the constitutive expression of ribonucleoprotein. All measurements were conducted three times for statistical analysis.

#### IFN-β assays

The A549, HBE, and HEp-2 cells were transfected with either control or ST6GAL1 siRNAs (10 nM). We measured the levels of IFN-β in culture supernatants 24 h later using an enzyme-linked immunosorbent assay (ELISA; PBL Biomedical Laboratories, Piscataway, NJ, USA). A long double-stranded RNA that induced the expression of IFN-β used as a positive control.

## Statistical analysis

All statistical analyses were performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). The significance of variability among experimental groups was determined using one-way ANOVA, the paired *t*-test, or the Mann–Whitney U test. All differences were considered statistically significant if the *P*-value was less than 0.05.

## Additional file

**Additional file 1: Table S1.** Nomenclature of 4 candidate siRNA duplexes targeting ST6GAL1 gene. **Table S2.** Real time RT-PCR primers and probes. **Figure S1.** Cells viability. **Figure S2.** Down regulation of influenza virus receptors SA  $\alpha$ 2,6Gal on transduced respiratory epithelium (HBE, Hep-2). **Figure S3.** Targeted siRNA transduced respiratory epithelium resist influenza virus challenge.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

DW contributed to the study design, data collection, most experiments, writing of the initial draft, and revising the manuscript. WB, YW, WG, and RL collected the preliminary data, and helped to perform some experiments. ZY and NZ participated in the study design, interpretation of the data, the study coordination, technical issues, and revision of the manuscript. All authors read and approved the final manuscript.

## Acknowledgments

This study was supported by a grant from the Guangdong Provincial Department of Education Foundation and partially by the National Science and Technology Major Project (Grant no. 2013ZX09304102).

## Author details

<sup>1</sup>State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, 1st KangDa Road, Guangzhou, China.

<sup>2</sup>Department of Respiratory, Affiliated Hospital of Guangdong Medical College, South 57, Renmin Avenue, Zhanjiang, China.

Received: 23 September 2013 Accepted: 19 March 2014

Published: 27 March 2014

## References

1. Peiris JS, Poon LL, Guan Y: Public health. Surveillance of animal influenza for pandemic preparedness. *Science* 2012, **335**(6073):1173–1174.
2. Situation updates - Pandemic (H1N1). 2009 [http://www.who.int/csr/disease/swineflu/en/]
3. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D: Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. *Antiviral Res* 2009, **83**(1):90–93.
4. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG: Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. *J Virol* 1995, **69**(8):4888–4897.
5. Ehrhardt C, Seyer R, Hrinčius ER, Eierhoff T, Wolff T, Ludwig S: Interplay between influenza A virus and the innate immune signaling. *Microbes Infect* 2010, **12**(1):81–87.
6. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, Jesus PD, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Sastre AG, Young JA, Palese P, Shaw ML, Chanda SK: Human host factors required for influenza virus replication. *Nature* 2010, **463**(7282):813–817.
7. Watanabe T, Watanabe S, Kawaoka Y: Cellular networks involved in the influenza virus life cycle. *Cell Host Microbe* 2010, **7**(6):427–439.
8. Landers JJ, Cao Z, Lee I, Piehler LT, Myc PP, Myc A, Hamouda T, Galecki AT, Baker JR: Prevention of influenza pneumonitis by sialic acid–conjugated dendritic polymers. *J Infect Dis* 2002, **186**(9):1222–1230.
9. Gambaryan AS, Tuzikov A, Piskarev V, Yamnikova S, Lvov D, Robertson J, Bovin N, Matrosovich M: Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 Influenza A and Influenza B viruses share a common high binding affinity for 6'-Sialyl( N-acetyl)lactosamine). *Virology* 1997, **232**(2):345–350.
10. Belsler JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Malakhov MP, Yu M, Fang F: DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. *J Infect Dis* 2007, **196**(10):1493–1499.
11. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P: The human sialyltransferase family. *Biochimie* 2001, **83**(8):727–737.
12. Weinstein J, Lee EU, McEntee K, Lai PH, Paulson JC: Primary structure of beta-galactoside alpha 2,6-sialyltransferase. Conversion of membrane-bound enzyme to soluble forms by cleavage of the NH2-terminal signal anchor. *J Biol Chem* 1987, **262**(36):17735–17743.
13. Lin S, Kemmner W, Grigull S, Schlag PM: Cell surface [alpha] 2, 6-sialylation affects adhesion of breast carcinoma cells. *Exp Cell Res* 2002, **276**(1):101–110.
14. Kemmner W, Hohaus K, Schlag PM: Inhibition of Gal [beta] 1, 4GlcNAc [alpha] 2, 6 sialyltransferase expression by antisense-oligodeoxynucleotides. *FEBS Lett* 1997, **409**(3):347–350.
15. Zheng B, Guan Y, Tang Q, Du C, Xie FY, He ML, Chan KW, Wong KL, Lader E, Woodle MC: Prophylactic and therapeutic effects of small interfering RNA targeting SARS coronavirus. *Antivir Ther* 2004, **9**(3):365–374.
16. Zielske SP, Stevenson M: Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. *J Virol* 2006, **80**(14):7275–7280.
17. Joost Haasnoot P, Cupac D, Berkhout B: Inhibition of virus replication by RNA interference. *J Biomed Sci* 2003, **10**(6):607–616.
18. Li B, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng B, Woodle MC: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. *Nature Med* 2005, **11**(9):944–951.
19. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. *Proc Natl Acad Sci* 2003, **100**(5):2718–2723.
20. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J: Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc Natl Acad Sci U S A* 2004, **101**(23):8676.
21. Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim A, Hanson BJ, Kwang J: Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. *Antivir Ther* 2009, **14**(7):911–921.
22. Nicholls JM, Peiris JS, Guan Y: Sialic acid and receptor expression on the respiratory tract in normal subjects and H5N1 and non-avian influenza patients. *Hong Kong Med J* 2009, **15**(3 Suppl 4):16–20.
23. Ge Q, Eisen HN, Chen J: Use of siRNAs to prevent and treat influenza virus infection. *Virus Res* 2004, **102**(1):37–42.
24. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. *Proc Natl Acad Sci U S A* 2004, **101**(7):1892.
25. Glaser L, Conenello G, Paulson J, Palese P: Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. *Virus Res* 2007, **126**(1–2):9–18.
26. Zeng J, Joo HM, Rajini B, Wrammert JP, Sangster MY, Onami TM: The generation of influenza-specific humoral responses is impaired in ST6Gal I-deficient mice. *J Immunol* 2009, **182**(8):4721–4727.
27. Gambaryan A, Tuzikov A, Pazynina G, Webster R, Matrosovich M, Bovin N: H5N1 chicken influenza viruses display a high binding affinity for Neu5Acalpha2-3Galbeta1-4(6-HSO3)GlcNAc-containing receptors. *Virology* 2004, **326**(2):310–316.
28. Kono M, Ohyama Y, Lee YC, Hamamoto T, Kojima N, Tsuji S: Mouse beta-galactoside alpha 2, 3-sialyltransferases: comparison of in vitro substrate specificities and tissue specific expression. *Glycobiology* 1997, **7**(4):469–479.
29. Kono M, Takashima S, Liu H, Inoue M, Kojima N, Young-Choon L, Hamamoto T, Tsuji S: Molecular cloning and functional expression of a fifth-type alpha 2, 3-



- sialyltransferase (mST3Gal V: GM3 synthase). *Biochem Biophys Res Commun* 1998, **253**(1):170–175.
30. Gambaryan A, Robertson J, Matrosovich M: **Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses.** *Virology* 1999, **258**(2):232–239.
  31. Chutinimitkul S, Herfst S, Steel J, Lowen AC, Ye J, van Riel D, Schrauwen EJA, Bestebroer TM, Koel B, Burke DF: **Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A (H1N1) virus affects receptor binding.** *J Virol* 2010, **84**(22):11802–11813.
  32. Schwardt O, Gao GP, Visekruna T, Rabbani S, Gassmann E, Ernst DB: **Substrate specificity and preparative use of recombinant rat ST3Gal III.** *J Carbohydr Chem* 2004, **23**(1):1–26.
  33. **Description of  $\alpha$ 2,3-(O)-sialyltransferase, rat, recombinant, S. frugiperda.** [<http://www.millipore.com/catalogue/item/566227-100miu#>]
  34. Glaser L, Stevens J, Zamarin D, Wilson IA, García-Sastre A, Tumpey TM, Basler CF, Taubenberger JK, Palese P: **A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity.** *J Virol* 2005, **79**(17):11533–11536.
  35. Monteararat Y, Suptawiwat O, Boonarkart C, Uprasertkul M, Auewarakul P, Viprakasit V: **Inhibition of H5N1 highly pathogenic influenza virus by suppressing a specific sialyltransferase.** *Arch Virol* 2010, **155**(6):889–893.
  36. **BLOCK-IT™ RNAi designer.** [<http://rnaidesigner.invitrogen.com/rnaiexpress/>]
  37. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: **Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.** *Nature* 2001, **411**(6836):494–498.
  38. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K: **Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides.** *Virology* 2000, **278**(2):587–596.
  39. Paulson JC, Rogers GN: **Resialylated erythrocytes for assessment of the specificity of sialyloligosaccharide binding proteins.** *Methods Enzymol* 1987, **138**:162–168.
  40. Payment P, Trudel M: *Methods and Techniques in Virology*. New York: Marcel Dekker; 1993.

doi:10.1186/1471-2180-14-78

**Cite this article as:** Wu *et al.*: Gene silencing of  $\beta$ -galactosamide  $\alpha$ -2,6-sialyltransferase 1 inhibits human influenza virus infection of airway epithelial cells. *BMC Microbiology* 2014 **14**:78.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

